Equities Analysts Set Expectations for Medtronic Q1 Earnings

Medtronic plc (NYSE:MDT - Free Report) - Equities researchers at William Blair dropped their Q1 2026 earnings per share (EPS) estimates for shares of Medtronic in a report released on Wednesday, May 21st. William Blair analyst M. Andrew now expects that the medical technology company will post earnings per share of $1.23 for the quarter, down from their prior forecast of $1.33. The consensus estimate for Medtronic's current full-year earnings is $5.46 per share. William Blair also issued estimates for Medtronic's Q2 2026 earnings at $1.33 EPS, Q3 2026 earnings at $1.37 EPS, Q4 2026 earnings at $1.60 EPS, FY2026 earnings at $5.54 EPS, Q1 2027 earnings at $1.33 EPS, Q2 2027 earnings at $1.39 EPS, Q4 2027 earnings at $1.76 EPS and FY2027 earnings at $5.94 EPS.

Medtronic (NYSE:MDT - Get Free Report) last issued its earnings results on Wednesday, May 21st. The medical technology company reported $1.62 EPS for the quarter, beating analysts' consensus estimates of $1.58 by $0.04. Medtronic had a return on equity of 14.07% and a net margin of 12.83%. The firm had revenue of $8.93 billion for the quarter, compared to analyst estimates of $8.81 billion. During the same quarter in the prior year, the firm earned $1.46 earnings per share. Medtronic's revenue for the quarter was up 3.9% on a year-over-year basis.

A number of other equities analysts have also weighed in on MDT. Citigroup upgraded Medtronic from a "neutral" rating to a "buy" rating and lifted their price objective for the company from $92.00 to $107.00 in a research note on Tuesday, March 4th. Mizuho reduced their price target on Medtronic from $100.00 to $98.00 and set an "outperform" rating for the company in a research report on Thursday, May 22nd. Royal Bank of Canada lowered their price objective on Medtronic from $105.00 to $101.00 and set an "outperform" rating on the stock in a research report on Thursday, May 22nd. Needham & Company LLC reaffirmed a "hold" rating on shares of Medtronic in a research note on Monday, May 19th. Finally, Wall Street Zen downgraded shares of Medtronic from a "buy" rating to a "hold" rating in a report on Saturday. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $96.07.

Medtronic Stock Performance

Shares of Medtronic stock traded up $0.29 during trading on Friday, hitting $81.47. 3,397,143 shares of the company's stock were exchanged, compared to its average volume of 6,804,670. Medtronic has a 52-week low of $75.96 and a 52-week high of $96.25. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.39 and a current ratio of 1.90. The stock has a market capitalization of $104.48 billion, a price-to-earnings ratio of 24.78, a PEG ratio of 2.22 and a beta of 0.81. The business has a 50-day simple moving average of $84.64 and a 200-day simple moving average of $86.31.

Institutional Investors Weigh In On Medtronic

Several institutional investors have recently bought and sold shares of the company. Olstein Capital Management L.P. increased its position in shares of Medtronic by 8.0% during the fourth quarter. Olstein Capital Management L.P. now owns 94,000 shares of the medical technology company's stock worth $7,509,000 after purchasing an additional 7,000 shares in the last quarter. Empowered Funds LLC grew its holdings in shares of Medtronic by 2.7% during the fourth quarter. Empowered Funds LLC now owns 105,822 shares of the medical technology company's stock worth $8,453,000 after buying an additional 2,778 shares in the last quarter. Caprock Group LLC grew its holdings in shares of Medtronic by 12.6% during the fourth quarter. Caprock Group LLC now owns 47,767 shares of the medical technology company's stock worth $3,849,000 after buying an additional 5,363 shares in the last quarter. Synergy Asset Management LLC raised its position in shares of Medtronic by 107.1% in the fourth quarter. Synergy Asset Management LLC now owns 227,802 shares of the medical technology company's stock valued at $19,353,000 after buying an additional 117,809 shares during the last quarter. Finally, Equitable Trust Co. lifted its stake in shares of Medtronic by 91.7% in the fourth quarter. Equitable Trust Co. now owns 39,645 shares of the medical technology company's stock worth $3,167,000 after buying an additional 18,968 shares in the last quarter. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Medtronic Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, July 11th. Investors of record on Friday, June 27th will be paid a $0.71 dividend. The ex-dividend date is Friday, June 27th. This is a positive change from Medtronic's previous quarterly dividend of $0.70. This represents a $2.84 dividend on an annualized basis and a yield of 3.49%. Medtronic's dividend payout ratio (DPR) is currently 78.45%.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.